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ABSTRACT 
Although the development of anticancer drugs has improved the outcomes of bone and soft 
tissue sarcomas, the clinical outcome of patients with relapsed sarcomas remains unsatisfactory due to 
therapeutic toxicities and resistance to anticancer drugs. Therefore, novel therapeutic modalities are 
needed to improve the outcome of patients with bone and soft tissue sarcomas. Dendritic cells present 
tumor antigens and stimulate immune responses, and immune cells, such as cytotoxic T lymphocytes, kill 
tumor cells by recognizing tumor antigens. However, immune-suppressive conditions by immune 
regulator PD-1, CTLA-4, and regulatory T cells help tumor growth and progression. In this report, current 
immunotherapies including cellular immunotherapy and checkpoint inhibitors are introduced, and the 
advantages and disadvantages of the treatments are discussed.   
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Current treatment of sarcomas  
Bone and soft tissue sarcomas are rare, heterogeneous solid tumors of mesenchymal origin. 
Current standard treatment options for bone and soft tissue sarcomas consist of surgical resection, 
chemotherapy, and radiation therapy. Before the introduction of chemotherapy, long-term survival 
occurred in only 20 to 40% of patients with bone sarcomas and in only 35% of patients with soft tissue 
sarcomas [1]. Since the 1970s, chemotherapy has significantly improved the outcomes of sarcomas, and a 
majority of the patients without metastasis at the time of initial diagnosis have long survival [1]. Five-year 
survival of 60 to 80% has been reported for patients receiving chemotherapy with surgical resection [2–6]. 
Despite intensive treatment, including chemotherapy, surgery, and radiation therapy, 6–15% of patients 
develop recurrent disease [7–10], and the outcome of the patients with recurrent or metastatic sarcomas 
remains poor [11]. Current treatment options are sometimes quite limited for patients with recurrent or 
metastatic sarcomas because of resistance to chemotherapy and organ disorders, such as kidney and heart 
disorders, caused by repeated chemotherapy. Although metastasectomy can be performed in patients with 
a small number of metastatic lesions, only a part of these patients has long term survival [12]. Although 
the efficacies of new anticancer agents for sarcomas were investigated in clinical trials [13–16], no 
remarkable data can currently be derived [17]. Therefore, novel therapeutic modalities are required for 
improving outcomes in patients with advanced sarcomas. Recent elucidation of the relationships between 
cancer cells and immune systems has contributed to the development of immunotherapy. Effects and 
limitations for immunotherapies for sarcomas are discussed in this report.  
 
Target of cellular immunotherapy 
Immune responses are classified into innate and adaptive immunity [18]. Innate immunity, 
comprising neutrophils, macrophages, and natural killer cells, provide initial defense against invading 
microbes. Cytokines mediate various activities of the cells involved in innate immunity. T and B 
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lymphocytes, key components of adaptive immunity following initial innate immunity, play central role in 
eliminating infectious pathogens, virus-infected cells, and cancer cells, and in generating antigen-specific 
memory cells. Adaptive immunity consists of humoral- and cell-mediated immunity. T lymphocytes 
recognize antigens presented by major histocompatibility complexes (MHCs) on the surface of dendritic 
cells (DCs). CD4+ and CD8+ T cells recognize antigens in the context of the MHC. Primed and activated 
T cells differentiate into mature effector cells, recognize virus infected cells and cancer cells, and 
eliminate them from the body.  
An effective immune system identifies cancer cells via detection of tumor-associated antigens 
(TAAs). TAAs are presented on the surface of the cell by human leukocyte antigen (HLA) class I and is 
targeted by cytotoxic T lymphocytes. Recent studies of TAAs have resulted in the identification of TAAs 
expressed by various cancer types including breast, lung, colon, liver, and lung. Cytotoxic T lymphocytes 
(CTL) are immune cells responsible for killing tumor cells. CTLs detect tumor cells by recognizing 
peptide fragments of endogenous proteins, which are presented to CTLs in complex with MHC class I 
molecules on the surface of the tumor cells. Antigen-presenting cells (APCs) induce the CTL response by 
delivering costimulatory signals between APCs and CTLs to CD4+ and CD8+ cells. On the other hand, 
DCs, one of the potent APCs, have the ability to take up apoptotic cells, process them, and present the 
tumor antigens. DCs play a pivotal role in the decision to promote or inhibit immune responses, including 
CTL responses [19]. In normal conditions, cancer cells with abnormal antigens are eliminated by the 
immune responses. On the other hand, insufficient function of the immune system exists since the early 
stages of cancer, and some cancer cells escape from the immune system. Furthermore, cancer cells 
suppress immune checkpoints and the immune system by recruitment of cells with immune-suppressive 
functions, such as regulatory T cells and myeloid-derived suppressor cells. 
Various subtypes of sarcomas express TAAs that allow the development of cellular 
immunotherapies [20]. In particular, some sarcomas have specific chromosomal translocations that may 
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serve as unique targets for immunotherapy [21]. Synovial sarcoma and myxoid/round cell liposarcoma 
are translation-driven malignancies and often express high levels of self-antigen, notably NY-ESO-1, a 
member of the MAGE and GAGE family, or developmental antigens such as the fetal acetylcholine 
receptor [22–26]. DC-based vaccines target TAAs including fusion proteins, such as EWS-FLI-1 
expressed in EWS or SYT-SSX2 expressed in synovial sarcoma [27,28]. These fusion proteins have been 
thought to be promising candidates as targets for immunotherapy. Although some TAAs have been 
identified in some sarcomas, a number of unknown TAAs may exist in sarcoma cells. In immunotherapy 
utilizing DCs, tumor lysate (TL) is commonly used as the pool of TAAs to sensitize immune cells, 
including DCs. 
Recent advancements in cancer immunity revealed the presence of immunity-inhibition in 
cancer patients [29]. To prevent an excessive immune response, inhibition or elimination of activated T 
lymphocyte is regulated by immune checkpoints. Activated T lymphocytes, particularly cytotoxic T 
lymphocytes, express immune checkpoint receptor-programmed cell death protein 1 (PD-1) [30], and 
inhibit their survival by signals from PD-ligand 1 (PD-L1) and PD-ligand 2 (PD-L2). The expression of 
PD-L1 is seen in DCs and non-immune cells, such as cancer cells, whereas the expression of PD-L2 was 
seen only in DCs, macrophages, and B lymphocytes [31]. In particular, cancer cells highly expressing 
PD-L1 and the interaction of PD-1 and PD-L1 downregulate the function of T cells expressing PD-1 
within the cancer microenvironment [32,33]. CTLA-4 is a regulatory molecule, involved in the 
downregulation of T cells and cytokine production [34]. Co-stimulatory signals by B7/CD28 binding 
result in T cell activation and chemokine production. Effector T cells regulate expression of CTLA-4 after 
induction of the costimulatory interaction between CD28 and B7 on APCs. However, regulatory T cells 
highly express CTLA-4 constitutively to suppress the activation of cytotoxic lymphocytes. The 
predominance of co-inhibitory pathways enables tumor cells to evade immune system control [35]. 
Self-tolerance and immunologic homeostasis are regulated by B7/CTLA-4 binding. Based on basic 
4 
 
research, anti-CTLA-4 and anti-PD-1 antibodies have been introduced for clinical use for several types of 
cancer [36]. 
 
Therapeutic vaccine in sarcomas 
The first report of cancer immunotherapy was performed by William B. Coley [37]. He 
observed that a patient with an inoperable sarcoma that suffered a Streptococcus pyogenes infection twice 
showed complete remission. Base on this case, Coley treated approximately 1000 patients with inoperable 
malignant tumors with live or inactivated bacteria, known as “Coley’s toxins”, achieving complete 
remission in 10% of the patients. In the 1970s, Marcove reported that immunization using autologous 
tumor lysate significantly improved overall survival and that 9 of 21 patients had long term survival [38]. 
In a clinical trial of tumor-specific peptide vaccination combined with IL-2 for patients with Ewing 
sarcoma and alveolar rhabdomyosarcoma, no clinical benefit and immunological response were observed 
[39]. A cocktail peptide vaccination phase II study for 20 patients with bone and soft tissue sarcoma 
showed that stable disease was observed in 6 of 20 patients, and that there was regression of pulmonary 
metastasis and long-survival in patients with malignant fibrous histiocytoma and synovival sarcoma, 
respectively [40]. A clinical vaccination trial for HLA-A24+ patients with refractory synovial sarcoma 
reported by Kawaguchi showed that 7 of 21 patients showed stable disease with minor immunological 
responses [41]. Although vaccination with antigenic peptides has some efficacy and potential to elicits T 
cell responses directed at vaccine peptides, the reported objective response rates are low. It is thought that 
immunological adjuvant agents are needed to improve the clinical response to vaccine therapy, 
 
Cytokine therapy for sarcomas 
 Immune system is regulated by cytokines, and cytokines such as interleukin-2 (IL-2) and 
interferons (IFNs) have been used for immunotherapy [42–44]. Ito reported that 2 of 3 patients with 
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metastatic osteosarcoma treated with human leukocyte interferon showed remission of the metastatic 
tumors [42]. Schwinger reported that high-dose IL-2 treatment in 4 patients with metastatic 
osteosarcomas and 2 patients with metastatic Ewing sarcoma showed 2 patients with osteosarcoma 
obtained complete remission [43]. However, all the patients showed adverse events such as fatigue, 
anorexia, diarrhea, nausea, vomiting, and fever, and the treatment had to be stopped in 2 patients. 
EURAMOS-1 study, a recent study in Europe, investigated the efficacy of the use of adjuvant 
chemotherapy with pegylated interferon alfa-2b (IFN-α-2b) in patients with osteosarcoma, and no 
significant improvement of the event-free survival by IFN-α-2b was observed in the study patients [44]. 
These studies indicate that cytokine therapies may improve the prognosis of bone and soft tissue sarcoma 
to some extent.  
 
Cellular immunotherapy for sarcomas 
Although immunotherapy as a novel modality for cancer treatment has been markedly 
developed, only a small number of clinical trials on cellular immunotherapy in patients with sarcoma 
have been reported (Table 1).  
In a phase 1 study of DC immunotherapy using DCs pulsed with TL, keyhole limpet 
hemocyanin (KLH), lipopolysaccharide, and interferon gamma (IFN-γ), immune responses were induced 
in 3 of the 6 patients and no serious adverse events were observed in the study patients [45]. Himoudi 
reported that a phase 1 trial of immunotherapy using DCs pulsed with TL and KLH showed that 
significant anti-tumor responses were induced in only 2 out of 12 patients with no evidence of clinical 
benefit [46]. Geiger reported that a phase 1 trial of TL-pulsed DCs in pediatric solid tumors showed 
significant regression of metastatic sites in 1 patient and stable disease in 5 patients out of 10 patients [47]. 
Suminoe reported DC-based immunotherapy using tumor-specific synthetic peptide or TL in 5 patients 
with refractory solid tumors (Ewing sarcoma, synovial sarcoma, and neuroblastoma) [48]. In the report, 
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one patient with Ewing sarcoma had a residual tumor disappear following DC therapy, whereas 4 patients 
had progression of the disease. Merchant reported a clinical trial of adjuvant immunotherapy using 
autologous lymphocytes and TL-pulsed DCs following standard antineoplastic treatment [49]. In the 
study, the five-year overall survival rate in patients with or without immunotherapy were 62% and 29%, 
respectively, although there was no statistical significance by multivariate analysis. We previously 
reported a phase 1/2 study of DC-based immunotherapy in 37 patients with refractory bone and soft tissue 
sarcoma [50]. In the study, DCs were treated with or without TL, TNF-α, or OK-432, a 
penicillin-inactivated and lyophilized preparation of Streptococcus pyogenes [51]. The study patients 
showed significant elevation of serum IFN-γ and serum IL-12 after the DC-based immunotherapy, and 
clinical responses (partial response and stable disease) were observed in 7 patients (20%) after the 
DC-based immunotherapy (stable disease in 6 patients and tumor regression in 1 patient), and no patients 
had severe adverse events [50]. In the previous studies of DC-based immunotherapy, no significant 
toxicity associated with the immunotherapy was reported, whereas some patients experienced induration 
at the injection site and fever. DC therapy may represent a feasible, generally well-tolerated therapy in 
patients with refractory sarcoma, owing to its safety and immunological responses. Although DC-based 
immunotherapy was effective only in a small part of the patients with advanced sarcoma, it can be a 
promising treatment for prevention of the relapse of sarcomas in patients.  
Recently, adoptive T cell transfer therapy showed a high response rate in patients with synovial 
sarcoma. Cancer germline antigen NY-ESO-1 is expressed in 10% to 50% of metastatic melanomas, lung, 
breast, prostate, thyroid, and ovarian cancers as well as in 70% to 80% of synovial cell sarcomas 
[22,25,26]. Robbins reported a clinical trial utilizing the adoptive transfer of autologous peripheral blood 
mononuclear cells (PBMC) that were retrovirally transduced with a high-affinity T cell receptor directed 
against NY-ESO-1. The study showed objective clinical responses (complete response and partial 
response) in 11 of 17 patients with synovial sarcoma [25]. In the study, no toxicity associated with the 
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transferred cells was observed, although all patients experienced transient neutropenia and 
thrombocytopenia associated with the adjuvant use of IL-2. Phase 1/2 clinical study of T cells expressing 
an HER2-specific chimeric antigen receptor in patients with HER2-positive sarcomas [52] showed that 4 
of 17 patients had stable disease for 12 weeks to 14 months without significant toxicity. Although 
immunotherapies using TAA-specific T cells resulted in a significant result for synovial sarcoma, the 
treatment can be used in only some bone and soft tissue sarcomas because TAA remains unknown in most 
type of sarcomas.  
 
Immune checkpoint inhibitors 
The expression of PD-1 and PD-L1 reflects antitumor immunity and associated with prognosis 
of the patients with various cancers. Nowicki reported that PD-1 and PD-L1 expressions was significantly 
higher in metastatic tumors than in primary tumors and that PD-1 positivity was significantly associated 
with progression-free survival in patients with synovial sarcoma [53]. Zheng reported that PD-1 was 
significantly upregulated in both peripheral CD4+ and CD8+ T cells from patients with osteosarcoma and 
that patients with metastasis showed significantly higher levels of PD-1 in CD4+ T cells than in those 
without metastasis [54]. High expression of PD-1 and PD-L1 were reported in pleomorphic sarcomas 
(50%), malignant peripheral nerve sheath tumors (50%), and Kaposi sarcomas (80%), whereas synovial 
sarcomas had only a low expression of PD-1 and PD-L1 (25%) [55]. Kim reported that high expression of 
PD-1 and PD-L1 was observed in undifferentiated sarcoma, angiosarcoma, epithelioid sarcoma, 
rhabdomyosarcoma, whereas only a low expression of PD-1 and PD-L1 was observed in myxoid 
liposarcoma, well-differentiated liposarcoma, and myxofibrosarcoma [56]. In the report, PD-1 and PD-L1 
expression were associated with clinical stage, distant metastasis, histological grade, poor differentiation 
of tumor, and tumor necrosis in patients with sarcomas, and PD-1 and PD-L1 expression significantly 
correlated with overall survival and event-free survival in patients with sarcoma. Pollack investigated the 
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expression of PD-1 and PD-L1 and tumor subtypes and reported that a high-grade tumor was associated 
with higher expression of PD-1 and PD-L1 [57]. In the report, high expression of PD-1 and PD-L1 was 
observed in undifferentiated pleomorphic sarcoma and leiomyosarcoma, whereas very few synovial 
sarcomas and myxoid/round cell liposarcomas were found to have high PD-L1 and PD-1 expression. 
Future studies are necessary to assess PD-1/PD-L1 as a predictive biomarker in patients with sarcomas. 
Among various kinds of immunotherapies, immune checkpoint inhibitors have shown marked 
anticancer effects on the advanced stages of some cancer types by inhibiting the escape phenomenon of 
the cancer immune response [58]. Previous studies also suggested that PD-1 and PD-L1 are promising 
targets for patients with sarcoma. However, there are only a few reports of checkpoint inhibitors for 
sarcoma (Table 2). Ben-Ami reported that a phase 2 trial of PD-1 inhibition with nivolumab in patients 
with advanced uterine leiomyosarcoma showed no objective response in 12 patients and grade 3-4 
toxicity related to the treatment in 3 patients [59]. On the other hand, Paoluzzi retrospectively investigated 
the effect of nivolumab in 24 patients with bone and soft tissue sarcoma. The study showed that 3 patients 
had partial responses, 9 patients had stable disease, and 12 patients had disease progression, and that 
grade 3-4 toxicity occurred in 5 patients [60].  
Ipilimumab, a human monoclonal antibody that inhibits CTLA-4 activity, has been used as an 
immunotherapy drug and has entered clinical trials for several cancers. In a phase 2 study, 6 patients with 
synovial sarcoma were treated with ipilimumab every 3 weeks. The endpoint of the study was response 
rate and secondary endpoints included determination of the clinical benefit rate and evaluation of 
NY-ESO-1-specific immunity. In the study patients, the progression-free survival period ranged from 0.5 
to 2.1 months, and neither clinical response nor evidence of serological or delayed type hypersensitivity 
to NY-ESO-1 was observed [61].  
Immune checkpoints may be a target of immunotherapy in patients with sarcomas. Although 
immune checkpoint inhibitors have shown marked effects in several cancer types, previous clinical 
9 
 
studies showed no significant clinical benefit in patients with sarcomas. Further studies on the immune 
response pathway and the indication of checkpoint inhibitors are demanded for improvement of the 
treatment of bone and soft tissue sarcoma. 
 
Future perspective 
Immunotherapy can be considered as the candidate of standard treatment including surgery, 
chemotherapy, and radiation therapy. Although the effect of cellular immunotherapy is seen in only a part 
of patients, it is a feasible, well-tolerated, and promising approach in the treatment of children with 
advanced sarcomas. Recent clinical and basic studies suggest that checkpoint inhibitors are promising 
treatments for advanced sarcomas, whereas checkpoint inhibitors have shown only a small benefit and 
severe side effects in some study patients. Most immunotherapies require a large cost and a technically 
difficult process, and the effect of immunotherapy can be observed in only a limited number of patients. 
To apply effective immunotherapies in the future, factors associated with immune responses should be 
investigated to estimate the response to immunotherapy in each patient. Furthermore, further exploration 
of innovative approach of combination therapy using multimodality immunotherapy is demanded to 
enhance their antitumor activity.  
 
Executive summary 
 Novel therapeutic modalities have been demanded to improve outcome of patients with bone and 
soft tissue sarcomas. Recent elucidation of the relationships between cancer cells and immune 
systems has contributed to the development of immunotherapy. 
 Immunotherapies, such as vaccinations, cytokine therapies, cellular immunotherapies, and immune 
checkpoint inhibitors have been investigated for bone and soft tissue sarcomas. However, the effect 
of immunotherapy can be observed in only a limited number of patients.  
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 Further studies on the immune response pathway and the indication of immunotherapies are 
demanded for improvement of the treatment of sarcomas. 
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Table 1. Clinical trials using cellular immunotherapy for sarcomas.  
 
Cell therapy Number of 
patients 








15 Pediatric solid 
tumors 














DCs pulsed with 



















37 Sarcoma DCs pulsed with 
TL/OK-432/TNF-
α (5×106 cells) 




























(grade 2: 24%; 
grade 3: 7%) 
and 
anaphylaxis 













19  OS (16), EWS 











(20), SS (18) 














DC: dendritic cell, TL: tumor lysate, PR: partial response, SD: stable disease, PD: progression of 
disease 
 
Table 2. Clinical trials using checkpoint inhibitors for sarcoma.  
 
Agent Number of 
patients 




24 Sarcoma nivolumab (3 




bilirubin elevation (1), ALT 
elevation (1), AST/ALT 
elevation (1), and 










mg/kg), every 2 
weeks 
Abdominal pain (1), serum 
amylase and lipase 





antibody [Maki, 2013] 
6 Synovial sarcoma Ipilimumab 
(3mg/kg), every 3 
weeks 
Vomiting and diarrhea (1) PD: 6/6  
 
 
 
